Previous close | 3.3400 |
Open | 3.3874 |
Bid | 3.2000 x 1000 |
Ask | 3.2800 x 1400 |
Day's range | 3.2100 - 3.4000 |
52-week range | 1.8600 - 9.0100 |
Volume | |
Avg. volume | 14,289 |
Market cap | 8.258M |
Beta (5Y monthly) | 0.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | -234.8200 |
Earnings date | 12 Feb 2024 - 16 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.00 |
Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec’s “Silence and Replace” DNA-directed RNA interference gene therapy platformHAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, tod
Key Insights Benitec Biopharma will host its Annual General Meeting on 6th of December Total pay for CEO Jerel Banks...
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday,